Keyword: Illumina

Grail is reportedly considering squeezing in another $1 billion in funding before going public in Hong Kong this year, according to Bloomberg.

The partners will use Illumina’s NGS capabilities to create IVDs that assess tumor mutation burden and other potentially predictive biomarkers.

Illumina will use TruSight Tumor 170 as the basis for a test that identifies the NTRK fusions and RET gene alterations targeted by Loxo’s drugs.

The financing equips Oxford Nanopore to scale up its operation as it moves deeper into territory colonized by Illumina and Pacific Biosciences.

Andrew Witty will lead Optum as CEO, Novartis' operations lead André Wyss steps down, Gilead bids farewell to longtime R&D lead Norbert Bischofberger.

Helix plans to expand its DNA test marketplace this year to offer over 50 products, including launches from companies like Mayo Clinic.

Illumina, the maker of DNA sequencers, unveiled its latest device with a price tag of just under $20,000.

Grail will start next year led by a CEO with 30 years of biopharma experience, having been run by a former Google executive until August.

Teva’s former chairman Peterburg resigns, OrbiMed founder Isaly steps down, Grail poaches Roche exec Cook as CEO.

The pact positions Biocartis to register its Idylla RAS tests as companion diagnostics for Amgen's colorectal cancer drug Vectibix.